Shattuck Labs Inc

Shattuck Labs Inc has a strong liquidity position, with a current ratio of 11.7 and $54.2 million in cash and equivalents, indicating a robust ability to meet short-term obligations. The company has no long-term debt, and its debt-to-equity ratio is 0.0, suggesting a conservative capital structure. However, the company has negative operating and free cash flows of -$39.9 million and -$45.2 million, respectively, which may limit its ability to fund operations and growth without external financing. The company's profitability metrics are weak, with a return on equity (ROE) of -59.24% and a return on assets (ROA) of -53.62%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets. The net loss of $48.8 million and operating loss of $51.5 million further underscore the company's financial challenges. These performance indicators are significantly below the industry median for biotechnology and medical research firms, which typically have positive ROE and ROA figures. Shattuck Labs Inc's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher risks if demand in its primary market or product line declines. The company's revenue of $1.0 million is relatively small, and there is no indication of significant geographic expansion or segment diversification in the near term. The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. The company's operating and net losses suggest that it is not currently generating sustainable revenue growth. The absence of long-term debt and the presence of $54.2 million in cash and equivalents may provide some flexibility for future growth initiatives, but the company will need to address its profitability and cash flow challenges to achieve long-term success. The risk assessment for Shattuck Labs Inc indicates low liquidity and dilution risks, with no immediate filing-based flags detected. However, the company's negative cash flows and significant net losses may increase the risk of future dilution if it needs to raise additional capital. The company has not issued any new shares recently, and there is no indication of a dilutive event in the near term. The absence of long-term debt and the presence of a strong cash position provide some buffer against liquidity risks. Recent events and disclosures for Shattuck Labs Inc include analyst estimates that suggest a wide range of price targets, from $7.00 to $18.00, with a mean recommendation of 2.00 (1=strong buy, 5=strong sell). The company has received six "buy" ratings and one "hold" rating, indicating some investor confidence despite its current financial challenges. There are no recent filings or transcripts that provide additional insight into the company's strategic direction or operational performance.